MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Suletud

SektorTervishoid

35.78 0.59

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

34.82

Max

36.09

Põhinäitajad
By Trading Economics
Sissetulek	11M 51M
Müük	39M 239M
P/E Sektori keskmine	12.073 90.831
Aktsiakasum	1.08
Kasumimarginaal	21.242
Töötajad	268
EBITDA	14M 73M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+14.32% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	24. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	517M 2.2B
Eelmine avamishind	35.19
Eelmine sulgemishind	35.78

Uudiste sentiment

By Acuity

50%

120 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. jaan 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15. jaan 2026, 00:00 UTC

Tulu

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14. jaan 2026, 23:47 UTC

Market Talk

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14. jaan 2026, 23:44 UTC

Market Talk

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14. jaan 2026, 23:39 UTC

Market Talk

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14. jaan 2026, 23:32 UTC

Market Talk

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14. jaan 2026, 22:56 UTC

Omandamised, ülevõtmised, äriostud

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14. jaan 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14. jaan 2026, 22:17 UTC

Market Talk

Global Equities Roundup: Market Talk

14. jaan 2026, 22:17 UTC

Market Talk

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14. jaan 2026, 22:09 UTC

Tulu

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14. jaan 2026, 22:08 UTC

Tulu

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14. jaan 2026, 22:08 UTC

Tulu

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14. jaan 2026, 21:53 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14. jaan 2026, 21:53 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14. jaan 2026, 21:52 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Announces Positive Profit Alert for 2025

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Citigroup Acting as Financial Advisor to WuXi XDC

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: Aims to Keep Listing Status of BioDlink

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14. jaan 2026, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

14. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. jaan 2026, 21:49 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14. jaan 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14. jaan 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Makes Cash Offer for BioDlink International

14. jaan 2026, 21:13 UTC

Market Talk

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14. jaan 2026, 20:30 UTC

Market Talk

Tulu

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14. jaan 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14. jaan 2026, 20:08 UTC

Market Talk

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14. jaan 2026, 19:33 UTC

Market Talk

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14. jaan 2026, 19:06 UTC

Market Talk

Tulu

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

14.32% tõus

12 kuu keskmine prognoos

Keskmine 43.75 USD 14.32%

Kõrge 55 USD

Madal 32 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

120 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.